日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer

TBCRC 035:一项随机 II 期药效学研究,评估标准剂量和减量帕博西尼联合内分泌治疗在激素受体 (HR) 阳性、既往接受过治疗的转移性乳腺癌患者中的疗效

Jacob, S; Mayer, E L; Kacik, N; Storniolo, A M; Isaacs, C; Mayer, I; Stearns, V; Nanda, R; Nangia, J; Chien, A J; Moasser, M; Melisko, M; Wabl, C; Muzikansky, A; Geradts, J; Dillon, D A; Park, B H; Krop, I; Wolff, A C; Kochupurakkal, B; Shapiro, G I; Rugo, H S

Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

在 II 期 I-SPY2 临床试验中,根据临床和分子特征分析 HR+/HER2- 高危早期乳腺癌 (EBC) 患者的病理完全缓解 (pCR) 率

Huppert, L A; Wolf, D; Yau, C; Brown-Swigart, L; Hirst, G L; Isaacs, C; Pusztai, L; Pohlmann, P R; DeMichele, A; Shatsky, R; Yee, D; Thomas, A; Nanda, R; Perlmutter, J; Heditsian, D; Hylton, N; Symmans, F; Van't Veer, L J; Esserman, L; Rugo, H S

Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer

蒽环类药物对基因组高危、淋巴结阴性、HR阳性/HER2阴性乳腺癌的影响

Chen, N; Freeman, J Q; Yarlagadda, S; Atmakuri, A; Kalinsky, K; Pusztai, L; Sparano, J A; Huo, D; Nanda, R; Howard, F M

Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States

在美国真实世界环境中,sacituzumab govitecan 对转移性三阴性乳腺癌患者中性粒细胞减少症的疗效及管理

Nanda, R; Yam, C; Spring, L; Bhave, M A; Ntalla, I; Valdez, T; Stwalley, B; Liang, C; Wu, W-H; Sjekloca, N; Sadetsky, N; Lai, C; Kalinsky, K

Evaluation of IoT based smart safety systems for women and children using machine learning techniques

利用机器学习技术评估基于物联网的妇女儿童智能安全系统

Wagh, Nanda R; Sutar, Sanjay R; Kadam, V J; Jadhav, S M; Yadav, A S; Pawar, V S

Identifying Barriers and Enablers for Nurse-Initiated Care for Designing Implementation at Scale in Australian Emergency Departments: A Mixed Methods Study

识别澳大利亚急诊科大规模实施护士主导护理的障碍和促进因素:一项混合方法研究

Kourouche, Sarah; Considine, Julie; Li, Ling; Murphy, Margaret; Shaban, Ramon Z; Lam, Mary K; Berendsen Russell, Saartje; Fry, Margaret; Aggar, Christina; Dinh, Michael M; Shetty, Amith; Shaw, Timothy; Seimon, Radhika V; Aryal, Nanda R; Hughes, James A; Varndell, Wayne; Curtis, Kate

Ten years survival results of randomized study comparing weekly vs. triweekly cisplatin with concurrent radiation in locally advanced carcinoma cervix

一项随机研究比较了每周一次与每三周一次顺铂联合放疗治疗局部晚期宫颈癌的十年生存率

Nanda, R; Katke, Aradhana; Thejaswini, B; Giri, G V; Pawar, Yashwant; Manjula, M V; Babu, Govind

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy

化疗-内分泌治疗前,预测II-III期激素受体阳性、HER2阴性(HR+/HER2-)乳腺癌对内分泌治疗的敏感性

Du, L; Yau, C; Brown-Swigart, L; Gould, R; Krings, G; Hirst, G L; Bedrosian, I; Layman, R M; Carter, J M; Klein, M; Venters, S; Shad, S; van der Noordaa, M; Chien, A J; Haddad, T; Isaacs, C; Pusztai, L; Albain, K; Nanda, R; Tripathy, D; Liu, M C; Boughey, J; Schwab, R; Hylton, N; DeMichele, A; Perlmutter, J; Yee, D; Berry, D; Van't Veer, L; Valero, V; Esserman, L J; Symmans, W F

Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes

低分子量荧光团水平与 2 型糖尿病成人患者临床因素及非诺贝特疗效的关系

Andrzej S Januszewski #, David Chen #, Russell S Scott, Rachel L O'Connell, Nanda R Aryal, David R Sullivan, Gerald F Watts, Marja-Riitta Taskinen, Philip J Barter, James D Best, R John Simes, Anthony C Keech, Alicia J Jenkins

Weekly vs. tri-weekly cisplatin based chemoradiation in carcinoma cervix: a prospective randomized study of toxicity and compliance

宫颈癌患者每周一次与每三周一次顺铂化疗放疗方案的毒性和依从性前瞻性随机研究:一项比较研究

Katke, Aradhana; Nanda, R; Thejaswini, B; Pasha, Tanveer; Giri, G V; Babu, Govind; Pawar, Yashwant